| Entity | Hematolymphoid neoplasia |
| Prognosis | CCR1 expression correlates with overall survival in the non-germinal center subtype of diffuse large B-cell lymphoma. In follicular lymphoma, high levels of CCR1 are associated with a shorter survival interval, and CCR1 is a marker of an immune switch between macrophages and a T cell-dominant response. |
| Oncogenesis | CCR1 is expressed in intraepithelial B cells of human tonsil and granulocytic/monocytic cells in the bone marrow. Immunohistochemical analysis of 944 cases of hematolymphoid neoplasia identified CCR1 expression in a subset of B- and T-cell lymphomas, plasma cell myeloma, acute myeloid leukemia, and classical Hodgkin lymphoma. In 13 patients with chronic lymphocytic leukemia (CLL), 9 with hairy cell leukemia (HCL), 5 with mantle cell lymphoma (MCL), 5 with marginal zone B-cell lymphoma (MZL), 6 with small lymphocytic lymphoma (SLL), and 5 with follicular cell lymphoma (FCL), flow cytometry analysis demonstrated that CCR1 was expressed in 70% of patients with CLL and 40% of those with HCL but was lacking in patients with MCL, MZL, SLL, and circulating normal B cells.
Circulating CD3+ T cells derived from healthy individuals and acute myelogenous leukemia patients with therapy-induced cytopenia after conventional chemotherapy or allogeneic stem cell transplantation showed no qualitative differences in CCR1 expression, that is, low expression for all the three groups. |
| | |
| Entity | Multiple myeloma |
| Prognosis | In 80 multiple myeloma (MM) patients with bone marrow samples, patients with active disease showed a significantly lower expression of CCR1, CCR2, as well as CXCR4 than patients with non-active disease. This chemokine receptor expression profile correlated with serum beta2-microglobulin, C-reactive protein and hemoglobin. Multivariate analysis identified the chemokine receptor expression profile as an independent prognostic factor. |
| Oncogenesis | Human MM cells express at least three different chemokine receptors that are functionally involved in MM cell migration, i.e. CCR1, CCR2 and CXCR4, some also CCR6 and CXCR3. cDNA arrays identified CCR1 and CCR2 are overexpressed in myeloma cells compared to autologous B-lymphoblastoid cell lines. The expression of CCR1 and the migration to their ligands, RANTES and MIP-1alpha, respectively, were demonstrated in MM cell lines and primary MM cells.
Osteoclasts (OCL) secrete high levels of CCL3 and MM cells the express CCR1, the interaction between which plays a key role in the pathogenesis of MM-related osteolytic bone disease. Through CCL3-CCR1 axis OCL cells promote OCL formation and, in turn, OCL enhance MM cell proliferation.
In murine models of MM, MIP-1alpha, an OCL stimulatory factor produced by primary MM cells, increases bone destruction and tumor burden, by interacting with chemokine receptors CCR1 and CCR5 that widely expressed in human OCL precursors, myeloma cell lines, and purified marrow plasma cells from MM patients. Neutralizing antibodies to CCR1 or CCR5 inhibited MIP-1alpha-induced OCL formation. Furthermore, MCP-3, which binds CCR1 but not CCR5, and the CCR1-specific antagonist, BX471, markedly inhibited OCL formation stimulated with MIP-1alpha. Anti-CCR1, anti-CCR5, or BX471 also inhibited the upregulation of beta1 integrin myeloma cells induced by MIP-1alpha, as well as the adherence of myeloma cells to stromal cells and IL-6 production by stromal cells in response to myeloma cells.
The oncogene c-maf is translocated in approximately 5%-10% of MM. By gene expression profiling, three c-maf target genes, cyclin D2, integrin beta7 and CCR1, were identified. |
| | |
| Entity | Hepatocellular carcinoma |
| Oncogenesis | Hepatic myofibroblast LI90 cells express and secrete MCP-1/CCL2. Through its receptors CCR1 and CCR2 as well, LI90 induces human hepatocellular carcinoma (HCC) Huh7 cell migration and invasion, which are strongly inhibited by heparin, beta-D-xyloside and anti-syndecan-1 and -4 antibodies. RANTES/CCL5 strongly stimulates the migration and the invasion of Huh7 cells by stimulating the tyrosine phosphorylation of focal adhesion kinase as well as activating matrix metalloproteinase-9, and to a lesser extent that of Hep3B cells. The RANTES-induced migration and invasion of Huh7 cells are also strongly inhibited by anti-CCR1 antibodies and heparin, as well as by beta-d-xyloside treatment of the cells, suggesting that CCR1 and glycosaminoglycans are involved in these events. We found that the miRNA-mediated knockdown expression of CCR1 significantly inhibited the invasive ability of and reduced the secretion of MMP-2 in hepatocellular carcinoma HCCLM3 cells, but only had a minor effect on the cellular proliferation. CCR1 expression was also detected on primary HCC cells and to a lesser degree, on endothelial cells in HCC tissues but not in normal liver tissues. Similarly, CCL3 expression was detected in HCC cells, endothelial cells, and to a lesser degree, fibroblast-like cells in HCC tissue, whereas only occasional vascular endothelial cells and inflammatory cells in normal liver tissues were weakly positive for CCL3. IL-1 enhances the local production of CCL3, which interact with CCR1 expressed on HCC cells, in an autocrine and/or paracrine manner. In a murine HCC model, injected tumor cells were transfected with HSV-thymidine kinase gene and then treated with ganciclovir (GCV). GCV treatment induced massive tumor cell apoptosis accompanied with intratumoral CCR1+CCR5+ dendritic cell infiltration. Tumor-infiltrating T cells and macrophages expressed CCL3, suggesting CCR1-CCL3 play a crucial role in the regulation of intratumoral dendritic cell accumulation and the subsequent establishment of tumor immunity following induction of tumor apoptosis by suicide genes. CCL3 and CCR1 are also expressed in 2 different models of HCC, i.e., N-nitrosodiethylamine (DEN)-induced HCC and HCC induced by hepatitis B virus. After DEN treatment, tumor foci number and sizes were remarkably reduced in CCR1- and CCL3-deficient mice, comparing with wild-type (WT) mice. Also, tumor angiogenesis markedly diminished, intratumoral Kupffer cells number reduced, MMP9 gene expression attenuated and MMP9+ cell numbers decreased in CCL3- and CCR1-deficient mice, as compared with WT mice. These observations suggest the contribution of the CCR1-CCL3 axis to HCC progression. |
| | |
| Entity | Colorectal cancer |
| Prognosis | The expression of CCR1 is higher in colorectal carcinoma than normal tissues, and correlates with lymph node metastasis, deep invasion, poor differentiation and advanced Dukes' stage. |
| Oncogenesis | Inactivation of TGF-beta family signaling within colon cancer increases CCL9 and promotes recruitment of the matrix metalloproteinase-expressing stromal cells that carry CCR1. Lack of CCR1 prevents the accumulation of MMP-expressing cells at the invasive front and suppresses tumor invasion. In a murine model of invasive colorectal cancer in which TGF-beta family signaling is blocked, CD34+ CCR1+ immature myeloid cell is recruited from the bone marrow to the tumor invasive front where expression of CCL9 is increased. These immature myeloid cells express MMP9, MMP2 and CCR1 and migrate toward the ligand CCL9. Lack of CCR1 prevents accumulation of CD34+ immature myeloid cell at the invasive front and suppresses tumor invasion. |
| | |
| Entity | Non-small cell lung cancer |
| Oncogenesis | CCR1 expression correlated with the aggressive phenotype of the non-small cell lung cancer (NSCLC) cells. CCR1 knockdown significantly suppressed the invasiveness of NSCLC cells and significantly reduced the expression of matrix metalloproteinase-9, but had only a minor effect on cell proliferation. |
| | |
| Entity | Oral squamous cell carcinoma |
| Oncogenesis | Expression of CCL3 and CCR1 is significant higher in oral squamous cell carcinoma compared with the normal controls. The percentages of CCL3+ and CCR1+ cells were observed to be similar in parenchyma and stroma in cases without lymph node metastasis when compared with lymph node metastasis positive cases. |
| | |
| Entity | Ovarian cancer |
| Oncogenesis | mRNA for CCR1, -2a, -2b, -3, -4, -5, and -8 was detected in cells from human ovarian cancer ascites. Further, flowcytometry showed CD14+ macrophages within ascites consistently expressed CCR1, -2, and -5, and >60% of all T cells expressed CCR1. Although ovarian cancer ascitic and blood monocyte/macrophages express CCR1, they failed to migrate in response to the RANTES. Compared with that of normal blood, cell surface expression level for CCR1 was higher in ascites. In a monocytic cell line in vitro, CCR1 mRNA expression was increased 5-fold by hypoxia. In 25 patients with ovarian cancer, CCR1 was detected in samples from 75% of patients, where CCR1 localised to macrophages and lymphocytes, and there was a correlation between numbers of CD8+ cells and CCR1+ cells. |
| | |
| Entity | Prostate cancer |
| Oncogenesis | Androgen receptor negative human prostate cancer cell line DU-145 cells selectively expressed CXCR4 and CCR1 at high levels compared with DU-145/AR cells that express androgen receptor. DU-145 showed vigorous migratory responses to CXCL12 and CCL3. In contrast, neither CXCL12 nor CCL3 affected the migration of DU-145/AR cells. |
| | |
| Entity | Breast cancer |
| Oncogenesis | The expression of CCR5 was higher than that of CCR1 in the peripheral blood mononuclear cells (PBMC) of healthy women, while the PBMC of the breast cancer patients showed overexpression of CCR1 and downregulation of CCR5. The differential effects of MIP-1alpha and MIP-1beta on the PBMC of healthy women and breast cancer patients correlated with the expression levels of CCR1 and CCR5 in these monocytes. In murine model of breast cancer, CCL5 (RANTES) was produced by the tumor cells, and its receptors, CCR1 and CCR5, were expressed by the infiltrating leukocytes. In mice treatment with Met-CCL5, an antagonist of CCR1 and CCR5, the volume and weight of tumors were significantly decreased compared with control-treated tumors. The total cell number obtained after collagenase digestion was decreased in Met-CCL5-treated tumors as was the proportion of infiltrating macrophages. Furthermore, chemokine antagonist treatment increased stromal development and necrosis. |
| | |
| Entity | Glioma |
| Oncogenesis | Co-cultured human glioma U87 cells induced an activated phenotype in HUVECs. These tumour-activated endothelial cells coordinately expressed matching pairs of receptors/ligands were found to be, including CCR1-RANTES axis. |
| | |
| Entity | Osteogenic sarcoma |
| Oncogenesis | The activities of phospholipase C (PLC), protein kinase C delta (PKCdelta) and NF-kappaB were enhanced by Lkn-1 (CCL15) stimulation on CCR1+ human osteogenic sarcoma cells. Inhibitors of G protein, PLC, PKCdelta and NF-kappaB inhibited the chemotactic activity of Lkn-1 on CCR1+ osteogenic sarcoma cells indicating that Lkn-1-induced chemotaxis involving these signaling pathways. |
| | |
| Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. |
| Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A. |
| J Immunol. 1998 Jul 1;161(1):342-6. |
| PMID 9647242 |
| |
| CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues. |
| Votta BJ, White JR, Dodds RA, James IE, Connor JR, Lee-Rykaczewski E, Eichman CF, Kumar S, Lark MW, Gowen M. |
| J Cell Physiol. 2000 May;183(2):196-207. |
| PMID 10737895 |
| |
| Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. |
| De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, Rossi JF, Mechti N, Klein B. |
| Blood. 2001 Aug 1;98(3):771-80. |
| PMID 11468178 |
| |
| Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. |
| Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. |
| Blood. 2001 Jun 1;97(11):3349-53. |
| PMID 11369623 |
| |
| Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. |
| Scotton C, Milliken D, Wilson J, Raju S, Balkwill F. |
| Br J Cancer. 2001 Sep 14;85(6):891-7. |
| PMID 11556842 |
| |
| Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active. |
| Vakili J, Standker L, Detheux M, Vassart G, Forssmann WG, Parmentier M. |
| J Immunol. 2001 Sep 15;167(6):3406-13. |
| PMID 11544332 |
| |
| Leukotactin-1/CCL15-induced chemotaxis signaling through CCR1 in HOS cells. |
| Ko J, Kim IS, Jang SW, Lee YH, Shin SY, Min DS, Na DS. |
| FEBS Lett. 2002 Mar 27;515(1-3):159-64. |
| PMID 11943214 |
| |
| Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas. |
| Lu P, Nakamoto Y, Nemoto-Sasaki Y, Fujii C, Wang H, Hashii M, Ohmoto Y, Kaneko S, Kobayashi K, Mukaida N. |
| Am J Pathol. 2003 Apr;162(4):1249-58. |
| PMID 12651617 |
| |
| A chemokine receptor antagonist inhibits experimental breast tumor growth. |
| Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. |
| Cancer Res. 2003 Dec 1;63(23):8360-5. |
| PMID 14678997 |
| |
| Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. |
| Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM. |
| Cancer Cell. 2004 Feb;5(2):191-9. |
| PMID 14998494 |
| |
| Human LZIP binds to CCR1 and differentially affects the chemotactic activities of CCR1-dependent chemokines. |
| Ko J, Jang SW, Kim YS, Kim IS, Sung HJ, Kim HH, Park JY, Lee YH, Kim J, Na DS. |
| FASEB J. 2004 May;18(7):890-2. Epub 2004 Mar 4. |
| PMID 15001559 |
| |
| Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. |
| Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, Pizzo P, Binotto G, Nicolardi L, Zambello R, Adami F, Agostini C, Semenzato G. |
| Blood. 2004 Jul 15;104(2):502-8. Epub 2004 Mar 4. |
| PMID 15001469 |
| |
| MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. |
| Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD. |
| Exp Hematol. 2005 Mar;33(3):272-8. |
| PMID 15730850 |
| |
| The clinical potential of chemokine receptor antagonists. |
| Ribeiro S, Horuk R. |
| Pharmacol Ther. 2005 Jul;107(1):44-58. (REVIEW) |
| PMID 15894378 |
| |
| Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. |
| Akashi T, Koizumi K, Nagakawa O, Fuse H, Saiki I. |
| Oncol Rep. 2006 Oct;16(4):831-6. |
| PMID 16969502 |
| |
| Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. |
| Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K. |
| Clin Exp Metastasis. 2006;23(5-6):291-300. Epub 2006 Nov 3. |
| PMID 17086356 |
| |
| Macrophage inflammatory protein (MIP)1alpha and MIP1beta differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy. |
| Nath A, Chattopadhya S, Chattopadhyay U, Sharma NK. |
| Cancer Immunol Immunother. 2006 Dec;55(12):1534-41. Epub 2006 Mar 4. |
| PMID 16518599 |
| |
| Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. |
| Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I. |
| Haematologica. 2006 Feb;91(2):200-6. |
| PMID 16461304 |
| |
| Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. |
| Yang X, Lu P, Fujii C, Nakamoto Y, Gao JL, Kaneko S, Murphy PM, Mukaida N. |
| Int J Cancer. 2006 Apr 15;118(8):1869-76. |
| PMID 16284949 |
| |
| SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. |
| Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H, Aoki M, Oshima M, Hattori M, Takabayashi A, Minato N, Taketo MM. |
| Nat Genet. 2007 Apr;39(4):467-75. Epub 2007 Mar 18. |
| PMID 17369830 |
| |
| Keeping out the bad guys: gateway to cellular target therapy. |
| Kitamura T, Taketo MM. |
| Cancer Res. 2007 Nov 1;67(21):10099-102. (REVIEW) |
| PMID 17974948 |
| |
| Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense. |
| Silva TA, Ribeiro FL, Oliveira-Neto HH, Watanabe S, Alencar Rde C, Fukada SY, Cunha FQ, Leles CR, Mendonca EF, Batista AC. |
| Oncol Rep. 2007 Nov;18(5):1107-13. |
| PMID 17914560 |
| |
| Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. |
| Sutton A, Friand V, Papy-Garcia D, Dagouassat M, Martin L, Vassy R, Haddad O, Sainte-Catherine O, Kraemer M, Saffar L, Perret GY, Courty J, Gattegno L, Charnaux N. |
| Mol Cancer Ther. 2007 Nov;6(11):2948-58. |
| PMID 18025279 |
| |
| MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. |
| Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC. |
| Blood. 2007 Nov 15;110(10):3744-52. Epub 2007 Aug 22. |
| PMID 17715391 |
| |
| Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion. |
| Wu X, Fan J, Wang X, Zhou J, Qiu S, Yu Y, Liu Y, Tang Z. |
| Biochem Biophys Res Commun. 2007 Apr 20;355(4):866-71. Epub 2007 Feb 15. |
| PMID 17336272 |
| |
| Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. |
| Byers RJ, Sakhinia E, Joseph P, Glennie C, Hoyland JA, Menasce LP, Radford JA, Illidge T. |
| Blood. 2008 May 1;111(9):4764-70. Epub 2008 Jan 3. |
| PMID 18174380 |
| |
| Chemo-angiogenic profile of bovine urinary bladder tumors distinguishes urothelial carcinomas from hemangiosarcomas. |
| Carvalho T, Elias AP, Nunes T, Peleteiro MC, Dias S. |
| Vet Immunol Immunopathol. 2008 Feb 15;121(3-4):344-58. Epub 2007 Oct 10. |
| PMID 18022698 |
| |
| Migration deficit in monocyte-macrophages in human ovarian cancer. |
| Freedman RS, Ma Q, Wang E, Gallardo ST, Gordon IO, Shin JW, Jin P, Stroncek D, Marincola FM. |
| Cancer Immunol Immunother. 2008 May;57(5):635-45. Epub 2007 Oct 10. |
| PMID 17926037 |
| |
| Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. |
| Iida N, Nakamoto Y, Baba T, Kakinoki K, Li YY, Wu Y, Matsushima K, Kaneko S, Mukaida N. |
| J Leukoc Biol. 2008 Oct;84(4):1001-10. Epub 2008 Jul 21. |
| PMID 18644849 |
| |
| Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors. |
| Olsnes AM, Ersvaer E, Ryningen A, Bruserud O. |
| Hematology. 2008 Dec;13(6):329-32. |
| PMID 19055860 |
| |
| Correlations of chemokine receptor CCR1 expression with metastasis of lymph nodes in colorectal carcinoma tissues. |
| Ma JA, Qiu ZH, Pei HP. |
| Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009 Aug;25(8):714-5. |
| PMID 19664396 |
| |
| CCR1 knockdown suppresses human non-small cell lung cancer cell invasion. |
| Wang CL, Sun BS, Tang Y, Zhuang HQ, Cao WZ. |
| J Cancer Res Clin Oncol. 2009 May;135(5):695-701. Epub 2008 Oct 30. |
| PMID 18972130 |
| |
| C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. |
| Anderson MW, Zhao S, Ai WZ, Tibshirani R, Levy R, Lossos IS, Natkunam Y. |
| Am J Clin Pathol. 2010 Mar;133(3):473-83. |
| PMID 20154287 |
| |
| Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. |
| Dagouassat M, Suffee N, Hlawaty H, Haddad O, Charni F, Laguillier C, Vassy R, Martin L, Schischmanoff PO, Gattegno L, Oudar O, Sutton A, Charnaux N. |
| Int J Cancer. 2010 Mar 1;126(5):1095-108. |
| PMID 19642141 |
| |
| Chemokine CCL3 facilitates the migration of hepatoma cells by changing the concentration intracellular Ca. |
| Yuan Y, Liu J, Liu Z, He Y, Zhang Z, Jiang C, Qian Q. |
| Hepatol Res. 2010 Apr 1;40(4):424-31. Epub 2010 Mar 4. |
| PMID 20236357 |
| |
